FDA Approval Opens U.S. TCAR Market to CGuard Prime
Key Facts
InspireMD announced on November 12, 2026, that the U.S. Food and Drug Administration had approved CGuard Prime for transcarotid artery revascularization, known as TCAR. The approval allows use of the system with its 80 cm delivery profile alongside an embolic protection system specified in the labeling. The company said use can begin with a protection system previously cleared by the FDA. The decision gives InspireMD a route into the U.S. TCAR market with the system, with sales expected to begin in the fourth quarter of 2026. The approval is based on clinical data from the CGUARDIANS II study, which tested the device with the ENROUTE system in patients at high surgical risk.
The U.S. multicenter, single-arm study enrolled 50 patients at 11 sites and used the FDA-cleared ENROUTE system. At 30-day follow-up, the study recorded acute device success in 100% of participants. No deaths, strokes, myocardial infarctions or stent thromboses were recorded during the stated follow-up period. Complete stent apposition was also observed in evaluable cases. These clinical results formed the basis for the new approval of CGuard Prime for TCAR procedures.
The approval permits use of CGuard Prime within a defined scope linked to the embolic protection system specified in the labeling. The company said use can begin with a protection system that has already received FDA clearance, allowing market entry independently of the investigational SwitchGuard device. This distinction matters because SwitchGuard is not available for sale in the United States and is being evaluated in the ongoing CGUARDIANS III study. InspireMD said the investigational device is "not available for sale." The system's initial launch will therefore use an existing protection device, while SwitchGuard remains under clinical evaluation.
InspireMD expects to begin U.S. sales of the system designed for TCAR procedures in the fourth quarter of 2026. That is the next commercial step following the approval announcement on November 12, according to the company's stated timeline. In September, the company said an FDA decision on the CGuard Prime version with an 80 cm delivery profile was expected in the fourth quarter. The decision has now been announced, while the start of sales remains the future milestone set out by the company. The available information did not include a sales forecast or a financial estimate of the launch's impact.
In trading, NSPR shares closed at $0.8 on November 11, 2026, according to EL7 data. That price is from the session before the approval announcement and therefore does not reflect the stock's response on the announcement day. A separate change announced on November 11 concerned the timing of the third-quarter results call, which was moved to 4:30 p.m. Eastern Time on November 12 from its previously announced time of 8:30 a.m. The company said the revised timing would allow management to provide a more comprehensive update on recent developments and commercial activities alongside the results. The call is scheduled to cover results and updates on the same day the company announced FDA approval.